2016;**387**(10031):1957-1966. DOI: 10.1016/s0140-6736(16)00097-0

[84] Pitchumoni C. Interdependence of nutrition and exocrine pancreatic function. In: Vay Liang W. Go, et al., editors. The Pancreas: Biology, Pathobiology, and Disease. Second ed. New York: Raven Press Ltd; 1993. DOI: 10.1007/978-3-642-79167-3\_48

[85] Pietzner M, Budde K, Rühlemann M, Völzke H, Homuth G, Weiss FU, et al. Exocrine pancreatic function modulates plasma metabolites through changes in gut microbiota composition. The Journal of Clinical Endocrinology & Metabolism. 2021;**106**(5):e2290-e22e8. DOI: 10.1210/ clinem/dgaa961

[86] Frost F, Weiss FU, Sendler M, Kacprowski T, Rühlemann M, Bang C, et al. The gut microbiome in patients with chronic pancreatitis is characterized by significant dysbiosis and overgrowth by opportunistic pathogens. Clinical and Translational Gastroenterology. 2020;**11**(9):e00232. DOI: 10.14309/ ctg.0000000000000232

[87] Akshintala VS, Talukdar R, Singh VK, Goggins M. The gut microbiome in pancreatic disease. Clinical Gastroenterology and Hepatology. 2019;**17**(2):290-295. DOI: 10.1016/j.cgh.2018.08.045

[88] Capurso G, Signoretti M, Archibugi L, Stigliano S, Delle FG. Systematic review and meta-analysis: Small intestinal bacterial overgrowth in chronic pancreatitis. United European Gastroenterology Journal. 2016;**4**(5):697- 705. DOI: 10.1177/2050640616630117

[89] Ní Chonchubhair HM, Bashir Y, Dobson M, Ryan BM, Duggan SN, Conlon KC. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic

pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018;**18**(4):379-385. DOI: 10.1016/j. pan.2018.02.010

[90] Talukdar R, Jandhyala SM, Reddy R, Arutla M, Reddy D. Altered gut microbiota in patients with chronic pancreatitis is associated with gut barrier dysfunction and metabolic abnormalities. Clinical Gastroenterology and Hepatology. 2017;**15**:153. DOI: 10.1016/j.cgh.2016.09.023

[91] Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut. 2023;**72**(2):338. DOI: 10.1136/ gutjnl-2022-327736

[92] Sánchez-Alcoholado L, Ramos-Molina B, Otero A, Laborda-Illanes A, Ordóñez R, Medina JA, et al. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers (Basel). 2020;**12**(6):1406. DOI: 10.3390/cancers12061406

[93] Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England Journal of Medicine. 2000;**343**(2):78-85. DOI: 10.1056/ nejm200007133430201

[94] Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. International Journal of Cancer. 2002;**99**(2):260-266. DOI: 10.1002/ ijc.10332

[95] Rattray NJW, Charkoftaki G, Rattray Z, Hansen JE, Vasiliou V,

*Intestinal Microbiomics in Physiological and Pathological Conditions DOI: http://dx.doi.org/10.5772/intechopen.110642*

Johnson CH. Environmental influences in the etiology of colorectal cancer: The premise of metabolomics. Current Pharmacology Reports. 2017;**3**(3):114- 125. DOI: 10.1007/s40495-017-0088-z

[96] Laqueur GL, McDaniel EG, Matsumoto H. Tumor induction in germfree rats with methylazoxymethanol (MAM) and synthetic MAM acetate. Journal of the National Cancer Institute. 1967;**39**(2):355-371. DOI: 10.1093/ jnci/39.2.355

[97] Reddy BS, Narisawa T, Wright P, Vukusich D, Weisburger JH, Wynder EL. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Research. 1975;**35**(2):287-290

[98] Reddy BS, Narisawa T, Weisburger JH. Colon carcinogenesis in germ-free rats with intrarectal 1,2-dimethylhydrazine and subcutaneous azoxymethane. Cancer Research. 1976;**36**(8):2874-2876

[99] Wong SH, Yu J. Gut microbiota in colorectal cancer: Mechanisms of action and clinical applications. Nature Reviews Gastroenterology & Hepatology. 2019;**16**(11):690-704. DOI: 10.1038/ s41575-019-0209-8

[100] Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Frontiers in Immunology. 2020;**11**:615056. DOI: 10.3389/ fimmu.2020.615056

[101] Saffarian A, Mulet C, Regnault B, Amiot A, Tran-Van-Nhieu J, Ravel J, et al. Crypt- and mucosa-associated core microbiotas in humans and their alteration in colon cancer patients. MBio. 2019;**10**(4):e01315-19. DOI: 10.1128/ mBio.01315-19

[102] Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012;**7**(6):e39743. DOI: 10.1371/journal. pone.0039743

[103] Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, DeStefano Shields CE, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host & Microbe. 2018;**23**(2):203-14.e5. DOI: 10.1016/j.chom.2018.01.007

[104] Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, et al. Multicohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018;**6**(1):70. DOI: 10.1186/ s40168-018-0451-2

[105] Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nature Medicine. 2019;**25**(4):679-689. DOI: 10.1038/s41591-019-0406-6

[106] Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nature Medicine. 2019;**25**(4):667-678. DOI: 10.1038/s41591-019-0405-7

[107] Bashir A, Miskeen AY, Bhat A, Fazili KM, Ganai BA. Fusobacterium nucleatum: An emerging bug in colorectal tumorigenesis. European Journal of Cancer Prevention. 2015;**24**(5):373-385. DOI: 10.1097/ cej.0000000000000116

[108] Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al.

Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;**65**(12):1973-1980. DOI: 10.1136/gutjnl-2015-310101

[109] Wei Z, Cao S, Liu S, Yao Z, Sun T, Li Y, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. Oncotarget. 2016;**7**(29):46158-46172. DOI: 10.18632/oncotarget.10064

[110] Lo C-H, Wu D-C, Jao S-W, Wu C-C, Lin C-Y, Chuang C-H, et al. Enrichment of Prevotella intermedia in human colorectal cancer and its additive effects with Fusobacterium nucleatum on the malignant transformation of colorectal adenomas. Journal of Biomedical Science. 2022;**29**(1):88. DOI: 10.1186/ s12929-022-00869-0

[111] Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. The ISME Journal. 2012;**6**(2):320-329. DOI: 10.1038/ ismej.2011.109

[112] Molska M, Reguła J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients. 2019;**11**(10). DOI: 10.3390/nu11102453

[113] Imen K, Meenakshi M, Alaoui-Jamali MA, Prakash S. In-Vitro characterization of the anti-cancer activity of the probiotic bacterium lactobacillus fermentum NCIMB 5221 and potential against colorectal cancer. Journal of Cancer Science & Therapy. 2015;**07**:224- 235. DOI: 10.4172/1948-5956.1000354

[114] van Munster IP, Tangerman A, Nagengast FM. Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation.

Digestive Diseases and Sciences. 1994;**39**(4):834-842. DOI: 10.1007/ bf02087431

[115] Dronamraju SS, Coxhead JM, Kelly SB, Burn J, Mathers JC. Cell kinetics and gene expression changes in colorectal cancer patients given resistant starch: A randomised controlled trial. Gut. 2009;**58**(3):413-420. DOI: 10.1136/ gut.2008.162933

[116] Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. The American Journal of Clinical Nutrition. 2007;**85**(2):488-496. DOI: 10.1093/ajcn/85.2.488

[117] Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology. 2018;**155**(2):529-41.e5. DOI: 10.1053/j. gastro.2018.04.018

[118] Hannigan GD, Duhaime MB, MTt R, Koumpouras CC, Schloss PD. Diagnostic potential and interactive dynamics of the colorectal cancer virome. MBio. 2018;**9**(6):e02248-18. DOI: 10.1128/ mBio.02248-18

[119] Luan C, Xie L, Yang X, Miao H, Lv N, Zhang R, et al. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. Scientific Reports. 2015;**5**:7980. DOI: 10.1038/srep07980

[120] Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;**68**(4):654-662. DOI: 10.1136/ gutjnl-2018-317178

[121] Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, *Intestinal Microbiomics in Physiological and Pathological Conditions DOI: http://dx.doi.org/10.5772/intechopen.110642*

Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host & Microbe. 2013;**14**(2):207-215. DOI: 10.1016/j.chom.2013.07.007

[122] Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nature Microbiology. 2019;**4**(12):2319-2330. DOI: 10.1038/ s41564-019-0541-3

[123] Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebocontrolled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterology. 2019;**19**(1):131. DOI: 10.1186/s12876-019-1047-4

[124] Ohara T, Yoshino K, Kitajima M. Possibility of preventing colorectal carcinogenesis with probiotics. Hepato-Gastroenterology. 2010;**57**(104):1411-1415

[125] Biarc J, Nguyen IS, Pini A, Gossé F, Richert S, Thiersé D, et al. Carcinogenic properties of proteins with proinflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis. 2004;**25**(8):1477-1484. DOI: 10.1093/carcin/bgh091

[126] Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host & Microbe. 2013;**14**(2):195-206. DOI: 10.1016/j. chom.2013.07.012

[127] Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;**42**(2):344-355. DOI: 10.1016/j.immuni.2015.01.010

[128] Cremonesi E, Governa V, Garzon JFG, Mele V, Amicarella F, Muraro MG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018;**67**(11):1984. DOI: 10.1136/gutjnl-2016-313498

[129] Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nature Communications. 2014;**5**:4724. DOI: 10.1038/ncomms5724

[130] Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America. 2010;**107**(25):11537-11542. DOI: 10.1073/ pnas.1001261107

[131] Martin OCB, Bergonzini A, D'Amico F, Chen P, Shay JW, Dupuy J, et al. Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells. Cellular Microbiology. 2019;**21**(12):e13099. DOI: 10.1111/ cmi.13099

[132] Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;**40**(1):128-139. DOI: 10.1016/j. immuni.2013.12.007

[133] Collins D, Hogan AM, Winter DC. Microbial and viral pathogens in colorectal cancer. The Lancet Oncology. 2011;**12**(5):504-512. DOI: 10.1016/ S1470-2045(10)70186-8

[134] Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;**504**(7480):446-450. DOI: 10.1038/ nature12721

[135] Buda A, Qualtrough D, Jepson MA, Martines D, Paraskeva C, Pignatelli M. Butyrate downregulates α2β1 integrin: A possible role in the induction of apoptosis in colorectal cancer cell lines. Gut. 2003;**52**(5):729. DOI: 10.1136/ gut.52.5.729

[136] Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, et al. The bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clinical Infectious Diseases. 2015;**60**(2):208-215. DOI: 10.1093/cid/ ciu787

[137] Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine. 2009;**15**(9):1016-1022. DOI: 10.1038/nm.2015

[138] Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;**15**(2):114-123. DOI: 10.1016/j. ccr.2008.12.018

[139] Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity. 2014;**41**(6):1052-1063. DOI: 10.1016/j. immuni.2014.11.009

[140] Scudamore CL, Jepson MA, Hirst BH, Miller HR. The rat mucosal mast cell chymase, RMCP-II, alters epithelial cell monolayer permeability in association with altered distribution of the tight junction proteins ZO-1 and occludin. European Journal of Cell Biology. 1998;**75**(4):321-330. DOI: 10.1016/s0171-9335(98)80065-4

[141] Zhang DM, Jiao RQ, Kong LD. High dietary fructose: Direct or indirect dangerous factors disturbing tissue and organ functions. Nutrients. 2017;**9**(4):335. DOI: 10.3390/nu9040335

[142] Cretoiu D, Ionescu RF, Enache RM, Cretoiu SM, Voinea SC. Gut microbiome, functional food, atherosclerosis, and vascular calcifications-is there a missing link? Microorganisms. 2021;**9**(9):1913. DOI: 10.3390/microorganisms9091913

[143] Lusis AJ. Atherosclerosis. Nature. 2000;**407**(6801):233-241. DOI: 10.1038/35025203

[144] Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis. 2011;**106**(5):858-867. DOI: 10.1160/th11-06-0392

[145] Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nature Reviews. Cardiology. 2017;**14**(2):79-87. DOI: 10.1038/nrcardio.2016.183

[146] Pastori D, Carnevale R, Nocella C, Novo M, Santulli M, Cammisotto V, et al. Gut-derived serum lipopolysaccharide is associated with enhanced risk of major adverse cardiovascular

*Intestinal Microbiomics in Physiological and Pathological Conditions DOI: http://dx.doi.org/10.5772/intechopen.110642*

events in atrial fibrillation: Effect of adherence to Mediterranean diet. Journal of the American Heart Association;**6**(6):e005784. DOI: 10.1161/ JAHA.117.005784

[147] Yamashita T, Yoshida N, Emoto T, Saito Y, Hirata KI. Two gut microbiotaderived toxins are closely associated with cardiovascular diseases: A review. Toxins (Basel). 2021;**13**(5):297. DOI: 10.3390/ toxins13050297

[148] Yoshida N, Yamashita T, Kishino S, Watanabe H, Sasaki K, Sasaki D, et al. A possible beneficial effect of Bacteroides on faecal lipopolysaccharide activity and cardiovascular diseases. Scientific Reports. 2020;**10**(1):13009. DOI: 10.1038/ s41598-020-69983-z

[149] Ding L, Chang M, Guo Y, Zhang L, Xue C, Yanagita T, et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids in Health and Disease. 2018;**17**(1):286. DOI: 10.1186/ s12944-018-0939-6

[150] Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circulation Research. 2020;**127**:553-570. DOI: 10.3390/ microorganisms9091913

[151] Trøseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. Journal of Internal Medicine. 2015;**277**(6):717-726. DOI: 10.1111/ joim.12328

[152] Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nature Reviews. Cardiology. 2019;**16**(3):137-154. DOI: 10.1038/s41569-018-0108-7

[153] Mutalub YB, Abdulwahab M, Mohammed A, Yahkub AM, Al-Mhanna SB, Yusof W, et al. Gut microbiota modulation as a novel therapeutic strategy in cardiometabolic diseases. Food. 2022;**11**(17):2575. DOI: 10.3390/foods11172575

[154] Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, et al. Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts. Journal of the American College of Cardiology. 2018;**71**(10):1184-1186. DOI: 10.1016/j.jacc.2017.12.057

[155] Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Failure. 2016;**4**(3):220-227. DOI: 10.1016/j. jchf.2015.10.009

[156] Ionescu RF, Boroghina SC, Cretoiu SM. Is there a link between the gut microbiome and arterial hypertension. Journal of Hypertension Research. 2021;**7**:12-17

[157] Miura K, Stamler J, Nakagawa H, Elliott P, Ueshima H, Chan Q, et al. Relationship of dietary linoleic acid to blood pressure. The international study of macro-micronutrients and blood pressure study [corrected]. Hypertension. 2008;**52**(2):408-414. DOI: 10.1161/ hypertensionaha.108.112383

[158] Tsukamoto I, Sugawara S. Low levels of linoleic acid and α-linolenic acid and high levels of arachidonic acid in plasma phospholipids are associated with hypertension. Biomedical Reports. 2018;**8**(1):69-76. DOI: 10.3892/ br.2017.1015

[159] Djoussé L, Arnett DK, Pankow JS, Hopkins PN, Province MA, Ellison RC. Dietary linolenic acid is associated with a lower prevalence of hypertension in the NHLBI family heart study. Hypertension. 2005;**45**(3):368-373. DOI: 10.1161/01. HYP.0000154679.41568.e6

[160] Sun S, Lulla A, Sioda M, Winglee K, Wu MC, Jacobs DR Jr, et al. Gut microbiota composition and blood pressure. Hypertension. 2019;**73**(5):998-1006. DOI: 10.1161/ hypertensionaha.118.12109

[161] Jin M, Qian Z, Yin J, Xu W, Zhou X. The role of intestinal microbiota in cardiovascular disease. Journal of Cellular and Molecular Medicine. 2019;**23**(4):2343- 2350. DOI: 10.1111/jcmm.14195

[162] Pluznick JL. Microbial shortchain fatty acids and blood pressure regulation. Current Hypertension Reports. 2017;**19**(4):25. DOI: 10.1007/ s11906-017-0722-5

[163] Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;**5**(1):14. DOI: 10.1186/s40168-016-0222-x

[164] Lu D, Zou X, Zhang H. The relationship between atrial fibrillation and intestinal flora with its metabolites. Frontiers in Cardiovascular Medicine. 2022;**9**:948755. DOI: 10.3389/ fcvm.2022.948755

[165] Wang L, Wang S, Zhang Q, He C, Fu C, Wei Q. The role of the gut microbiota in health and cardiovascular diseases. Molecular Biomedicine. 2022;**3**(1):30. DOI: 10.1186/ s43556-022-00091-2

[166] Drapkina OM, Yafarova AA, Kaburova AN, Kiselev AR. Targeting gut microbiota as a novel strategy for prevention and treatment of hypertension, atrial fibrillation and

heart failure: Current knowledge and future perspectives. Biomedicine. 2022;**10**(8):2019. DOI: 10.3390/ biomedicines10082019

[167] Zhang J, Zuo K, Fang C, Yin X, Liu X, Zhong J, et al. Altered synthesis of genes associated with short-chain fatty acids in the gut of patients with atrial fibrillation. BMC Genomics. 2021;**22**(1):634. DOI: 10.1186/s12864-021-07944-0

[168] Ballini A, Scacco S, Boccellino M, Santacroce L, Arrigoni R. Microbiota and obesity: Where are we now? Biology (Basel). 2020;**9**(12):415. DOI: 10.3390/ biology9120415

[169] Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States of America. 2005;**102**(31):11070-11075. DOI: 10.1073/ pnas.0504978102

[170] Ahmad A, Riaz S, Tanveer M. Obesity and gut microbiota. In: Effect of Microbiota on Health and Disease. London: IntechOpen; 2022. DOI: 10.5772/intechopen.105397

[171] Ojeda P, Bobe A, Dolan K, Leone V, Martinez K. Nutritional modulation of gut microbiota - the impact on metabolic disease pathophysiology. The Journal of Nutritional Biochemistry. 2016;**28**:191- 200. DOI: 10.1016/j.jnutbio.2015.08.013

[172] Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. The American Journal of Clinical Nutrition. 2011;**94**(1):58-65. DOI: 10.3945/ajcn.110.010132

[173] Kalliomäki M, Collado MC, Salminen S, Isolauri E. Early differences
